Effective Inhibition of TDP‐43 Aggregation by Native State Stabilization
Angewandte Chemie International Edition · 2024
DOI: 10.1002/anie.202314587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Lixin Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Fédérale…. Hauptthemen laut MEDLINE: TDP-43 Proteinopathies, Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: École Polytechnique Fédérale de Lausanne.
Abstract (Originalsprache)
Preventing the misfolding or aggregation of transactive response DNA binding protein with 43 kDa (TDP‐43) is the most actively pursued disease‐modifying strategy to treat amyotrophic lateral sclerosis and other neurodegenerative diseases. In this work, we provide proof of concept that native state stabilization of TDP‐43 is a viable and effective strategy for treating TDP‐43 proteinopathies. Firstly, we leveraged the Cryo‐EM structures of TDP‐43 fibrils to design C‐terminal substitutions that disrupt TDP‐43 aggregation. Secondly, we showed that these substitutions (S333D/S342D) stabilize monomeric TDP‐43 without altering its physiological properties. Thirdly, we demonstrated that binding native oligonucleotide ligands stabilized monomeric TDP‐43 and prevented its fibrillization and phase separation in the absence of direct binding to the aggregation‐prone C‐terminal domain. Fourthly, we showed that the monomeric TDP‐43 variant could be induced to aggregate in a controlled manner, which enabled the design and implementation of a high‐throughput screening assay to identify native state stabilizers of TDP‐43. Altogether, our findings demonstrate that different structural domains in TDP‐43 could be exploited and targeted to develop drugs that stabilize the native state of TDP‐43 and provide a platform to discover novel drugs to treat TDP‐43 proteinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Rte Cantonale, 1015, Lausanne, Switzerland.
- Chemogenomic and Biological Screening Core Facility, Institut Pasteur, Université Paris Cité, CNRS, UMR 3523, C2RT, Paris, France.
- Protein Platform, Faculty of Medicine, University of Geneva, 1 Rue Michel Servet, 1211, Geneva, Switzerland.
ORCID-Profile: Lixin Yang, Yllza Jasiqi, Agnès Zettor, Oscar Vadas, Jeanne Chiaravalli, Fabrice Agou, Hilal A Lashuel
Förderung
- École Polytechnique Fédérale de Lausanne
Zitieren
APA
Yang, L., Jasiqi, Y., Zettor, A., Vadas, O., Chiaravalli, J., Agou, F., & Lashuel, H. A. (2024). Effective Inhibition of TDP‐43 Aggregation by Native State Stabilization. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202314587
Vancouver
Yang L, Jasiqi Y, Zettor A, Vadas O, Chiaravalli J, Agou F, et al. Effective Inhibition of TDP‐43 Aggregation by Native State Stabilization. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202314587
BibTeX
@article{Yang2024,
author = {Yang, Lixin and Jasiqi, Yllza and Zettor, Agnès and Vadas, Oscar and Chiaravalli, Jeanne and Agou, Fabrice and Lashuel, Hilal A},
title = {Effective Inhibition of TDP‐43 Aggregation by Native State Stabilization},
journal = {Angewandte Chemie International Edition},
year = {2024},
doi = {10.1002/anie.202314587}
}
EUVIMED